2016
Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials
Bouras G, Jhamnani S, Ng VG, Haimi I, Mao V, Deible R, Cao S, Sudhir K, Lansky AJ. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheterization And Cardiovascular Interventions 2016, 89: 984-991. PMID: 27545721, DOI: 10.1002/ccd.26711.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsLong coronary lesionsTarget lesion failurePercutaneous coronary interventionAcademic Research ConsortiumMean lesion lengthCoronary lesionsXIENCE VCoronary interventionStent thrombosisLesion lengthRate of TLFControl groupSecond generation drug eluting stentsLong lesion groupAdverse cardiac eventsProbable stent thrombosisPrimary outcome measureCoronary stent systemDrug eluting stentsLesion failureCardiac eventsPooled analysisWorse outcomesLesion group
2013
Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years
Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. The American Journal Of Cardiology 2013, 111: 1580-1586. PMID: 23499270, DOI: 10.1016/j.amjcard.2013.01.330.Peer-Reviewed Original ResearchConceptsSPIRIT IV trialMajor adverse cardiac eventsAdverse cardiac eventsClinical outcomesXIENCE VTarget lesionsCardiac eventsNovo native coronary artery lesionsIschemia-driven target vessel revascularizationTwo-year clinical outcomesNative coronary artery lesionsSPIRIT IIISide branchesXIENCE V EverolimusTarget lesion failureTarget vessel revascularizationCoronary artery lesionsPercutaneous coronary interventionSuperior clinical outcomesTreatment of patientsCoronary stent systemDrug-eluting stentsDiverse patient populationsEverolimus-ElutingSPIRIT IV
2011
Low Stent Thrombosis Risk with the XIENCE V® Everolimus‐Eluting Coronary Stent: Evidence from Randomized and Single‐Arm Clinical Trials
BEZENEK S, HERMILLER J, LANSKY A, YAQUB M, HATTORI K, CAO S, SOOD P, SUDHIR K. Low Stent Thrombosis Risk with the XIENCE V® Everolimus‐Eluting Coronary Stent: Evidence from Randomized and Single‐Arm Clinical Trials. Journal Of Interventional Cardiology 2011, 24: 326-341. PMID: 21443551, DOI: 10.1111/j.1540-8183.2011.00628.x.Peer-Reviewed Original ResearchConceptsEverolimus-Eluting Coronary Stent SystemDual antiplatelet therapyXIENCE VST ratesRisk factorsLow stent thrombosis ratesSingle-arm clinical trialOccurrence of STStent thrombosis riskAcademic Research ConsortiumStent thrombosis ratesPotential risk factorsCoronary stent systemLow ST ratesHigh compliance rateSPIRIT FIRSTAntiplatelet therapyThrombosis rateSPIRIT trialComplex patientsThrombosis riskClinical trialsStent systemThin strut designDrug usageThree-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)
Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, Stone GW. Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial). The American Journal Of Cardiology 2011, 107: 841-848. PMID: 21255760, DOI: 10.1016/j.amjcard.2010.10.068.Peer-Reviewed Original ResearchConceptsTarget vessel failure rateSPIRIT III trialXIENCE VIII trialsClinical outcomesLow major adverse cardiac event rateMajor adverse cardiac event ratesAdverse cardiac event ratesMajor adverse cardiac eventsTAXUS paclitaxel-eluting stentAdverse cardiac eventsCardiac event rateCoronary artery lesionsLong-term complicationsPaclitaxel-eluting stentsThree-year resultsLesion revascularizationArtery lesionsCardiac eventsComplication rateStent thrombosisTreatment armsClinical benefitTaxus stentSubset analysisLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R, Lansky AJ, Cutlip DE, Sudhir K, Stone GW. Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial). The American Journal Of Cardiology 2011, 107: 833-840. PMID: 21247538, DOI: 10.1016/j.amjcard.2010.10.069.Peer-Reviewed Original ResearchMeSH KeywordsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsLogistic ModelsMaleMiddle AgedPaclitaxelProspective StudiesSingle-Blind MethodSirolimusSurvival RateTreatment OutcomeTubulin ModulatorsUnited StatesConceptsPaclitaxel-eluting stentsMajor adverse cardiovascular eventsSPIRIT III trialAdverse cardiovascular eventsCardiovascular eventsIII trialsPrimary clinical end pointLimited long-term dataTarget lesion revascularizationTarget vessel failureEvent-free survivalClinical end pointsEverolimus-Eluting StentsLong-term safetyLesion revascularizationCardiac deathCoronary arteryMyocardial infarctionSPIRIT IIClinical trialsEfficacy profileUnited States sitesLandmark analysisTerm safetyXIENCE V
2010
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention 2010, 5: 788-94. PMID: 20142192, DOI: 10.4244/eijv5i7a132.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPaclitaxelProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsTAXUS paclitaxel-eluting stentTarget vessel failureAngiographic late lossLate lossDiameter stenosisIII studyPooled analysisSPIRIT IIAdverse cardiac eventsSegment late lossStent late lossCoronary artery diseaseEES groupCardiac eventsArtery diseaseFemale patientsPES groupPatient levelClinical dataXIENCE VStent typeTwo-year analysisWomen
2009
Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry
Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. Catheterization And Cardiovascular Interventions 2009, 75: 179-186. PMID: 19877267, DOI: 10.1002/ccd.22259.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProspective StudiesRegistriesRisk AssessmentSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsTarget vessel failureSegment late lossSPIRIT III trialLarge coronary arteriesPaclitaxel-eluting stentsLate lossCoronary arteryIII trialsXIENCE VDe novo native coronary artery lesionsNovo native coronary artery lesionsNative coronary artery lesionsPE armSPIRIT IIIAdverse cardiac eventsCoronary artery lesionsAdverse clinical eventsAngiographic late lossEES patientsNoninferior ratesPrimary endpointAngiographic outcomesArtery lesionsCardiac eventsGender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:
Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW. Gender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:. Catheterization And Cardiovascular Interventions 2009, 74: 719-727. PMID: 19530147, DOI: 10.1002/ccd.22067.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCardiovascular DiseasesCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateLinear ModelsLogistic ModelsMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeWomen's HealthConceptsSPIRIT III trialIII trialsXIENCE VTaxus stentXience V stentTVF rateTAXUS paclitaxel-eluting stentRate of MACECoronary artery lesionsStent thrombosis ratesPercutaneous coronary interventionStent late lossPaclitaxel-eluting stentsCoronary stent systemHigher MACEMore hypertensionAngiographic characteristicsArtery lesionsCoronary interventionThrombosis rateAngiographic resultsClinical outcomesClinical benefitStent placementSubset analysis